|
Egypt Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Egypt Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Egypt.
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Egyptian pharmaceutical and healthcare industry.
Competitive intelligence, Egyptian pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Egyptian market.
The Egypt Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Egypt Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Egyptian pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Egypt to test other views – a key input for successful budgeting and strategic business planning in the Egyptian pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Egyptian Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Egypt.
- Exploit The Latest Competitive Egyptian Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Egypt.
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Egypt Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| Egypt Pharmaceuticals And Healthcare Industry SWOT |
| Egypt Political SWOT |
| Egypt Economic SWOT |
| Egypt Business Environment SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Middle East And Africa Pharmaceutical Business Environment Ratings |
| Limits To Potential Returns |
| Risks To Realisation Of Returns |
Chapter - Market Summary |
| Regulatory Regime |
| Intellectual Property Developments |
| Table: Losses Due To Counterfeit Drugs In MEA, Moving Annual Total Ending September 2006 |
| IP Shortcomings |
| Counterfeit Medicines |
| Free Trade Agreements |
| Pricing Regime |
| Reimbursement Regime |
| Recent Pricing And Reimbursement Developments |
Chapter - Industry Developments |
| Epidemiology |
| Healthcare Sector |
| Healthcare Insurance |
| Pharmaceutical Sector |
| Domestic Manufacturing |
| Foreign Manufacturing Sector |
| Recent Pharmaceutical Industry Developments |
| Retail Pharmacies |
| Herbal And OTC Medicine |
| Research And Development Activity |
| Medical Devices |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: Egypt – Drug Expenditure Indicators, 2003-2013 |
| Key Growth Factors – Industry |
| Table: Egypt – Health Expenditure Indicators, 2003-2013 |
| Key Growth Factors – Macroeconomic |
| Table: Egypt - Economic Activity |
| Prescription Drug Market Forecast |
| Table: Egypt Prescription Drug Market 2003-2013 |
| Table: Egypt – Prescription Market Indicators, 2003-2013 (EYPmn unless otherwise stated) |
| OTC Drug Market Forecast |
| Table: Egypt - OTC Drug Market Indicators, 2003-2013 (EGPmn unless otherwise stated) |
| Patented Drug Market Forecast |
| Table: Egypt – Patented Drug Market Indicators, 2003-2013 |
| Generic Drug Market Forecast |
| Table: Egypt - Generics Market Indicators, 2003-2013 |
| Medical Device Market Forecast |
| Pharmaceutical Export/Import Market Forecast |
| Table: Egypt - Pharmaceutical Trade Balance, 2003-2013 (US$mn) |
| Other Healthcare Data |
| Table: Egypt – Other Health Indicators, 2003-2013 |
| Key Risks To BMI Forecasts |
Chapter - Competitive Landscape |
| Company Monitors |
| Multinational Profiles |
| GlaxoSmithKline (GSK) |
| Sanofi-Aventis |
| Pfizer |
| Novartis |
| Bristol-Myers Squibb (BMS) |
| Merck & Co |
| AstraZeneca |
| Domestic Companies |
| Egyptian International Pharmaceutical Industries Co (EIPICO) |
| SEDICO |
| Alexandria Pharmaceuticals |
| Amoun Pharmaceutical (APC) |
| Holding Company for Biological Products & Vaccines (Vacsera) |
| Misr Pharmaceuticals |
Chapter - Country Snapshot: Egypt Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education And Healthcare |
| Table: Education, 2002-2005 |
| Table: Vital Statistics, 2005-2010 |
| Section 3: Labour Market And Spending Power |
| Table: Employment Indicators, 2001-2006 |
| Table: Consumer Expenditure, 2000-2012 (US$) |
| Table: Average Annual Wages, 2000-2012 |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Egypt Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
For this Q209 Pharmaceutical and Healthcare Report for Egypt, BMI forecasts that drug spending will increase from US$2.34bn in 2008 to US$4.10bn by 2013, representing a compound annual growth rate (CAGR) of 11.8% over the five year period. We believe the main drivers for growth will be the expected health reform that will take place in July 2009, with per capita expenditure on medicines expected to reach US$49.40 by 2013. We note that public sector health spending will only increase marginally from 40.3% to 45.6% of the total government expenditure. The healthcare sector in Egypt is moving toward a total overhaul as the Ministry of Health steers its involvement into a more regulatory role. However we maintain a positive outlook for the proposed national healthcare insurance scheme as free care will still be offered to the lowest income groups. Meanwhile the lack of birth control and resulting rising population are increasing demand for services, and BMI would encourage the state to address reproductive health awareness as a means of lowering the burden on health facilities.
During January 2009, the Ministry of Health confirmed that pharmaceutical firms will have higher fees when registering products to be imported, including all medicines and medical devices. The Ministry added that only private drug manufacturers will be affected by the fees, with consumer prices remaining largely unaffected. BMI notes that the increase fees have not been fully clarified by the Ministry, and would urge it to do so in the current climate of price anxiety by the population.
The higher fees are designed to reduce the number of applications sent to the ministry for medical equipment and drugs; however BMI cautions that this may negatively affect the healthcare system by restricting choice. As a result, private firms may selectively opt for more expensive products to maximise profits, reducing affordability for consumers in the longer term.
The Egyptian government will pass legislation by the end of July 2009 to enforce universal health insurance for the population. BMI welcomes this reform; however, we note the government has been discussing policies to ensure equitable access to medical services with fervour since 2006. Without any significant progress, it remains uncertain whether implementation will take place before the end of the year.
The population currently has access to free basic healthcare; however, the quality of services is often relatively poor as state-owned hospitals are insufficiently funded. To offset this, the Ministry of Health has resorted to charging the 48% of people who are uninsured for using medical equipment, including catheters, syringes and bed linen. According to the World Health Organization (WHO), 95% of private healthcare spending was on upfront fees during 2006. In addition, private health coverage spending decreased from US$12.7mn in 2000 to US$9.2mn by 2006. This approach has been harshly criticised as a means of phasing in private care. Absolute free insurance is only offered to newborns, children and widowers.
|
Egypt Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |